Indolo[2′,3′:3,4]pyrido[2,1-b]quinazoline compound and use thereof

ChangeBridge: Patent Grants - Organic Chemistry (C07D)

Published March 31st, 2026

Detected March 31st, 2026

Summary

USPTO granted patent US12590093B2 to the Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences, covering an indolo[2′,3′:3,4]pyrido[2,1-b]quinazoline compound for treating cardiovascular and cerebrovascular diseases. The patent lists 13 inventors and contains 4 claims, with applications including increasing expression of AMPK, ABCA1, and SR-BI, and inhibiting NLRP3, IL-1β, NF-κB, and MAPKs.

View original document View source feed page

What changed

USPTO issued Patent No. US12590093B2 to the Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences, for an indolo[2′,3′:3,4]pyrido[2,1-b]quinazoline compound (general formula I). The patent covers use in manufacturing medicaments for treating cardiovascular/cerebrovascular diseases, formulations for increasing expression of AMPK, ABCA1, and SR-BI, and anti-inflammatory applications. The patent was granted March 31, 2026, with Application No. 17767218 filed September 27, 2020.

This patent grant establishes intellectual property rights for the Chinese Academy of Medical Sciences. Pharmaceutical companies developing cardiovascular treatments should conduct freedom-to-operate analyses to ensure their compounds or methods do not infringe this patent. Companies with overlapping cardiovascular drug pipelines should review this patent landscape to assess potential licensing needs or design-around strategies.

Source document (simplified)

← USPTO Patent Grants

Indolo[2′,3′:3,4]pyrido[2,1-b]quinazoline compound and use thereof

Grant US12590093B2 Kind: B2 Mar 31, 2026

Assignee

INSTITUTE OF MEDICINAL BIOTECHNOLOGY CHINESE ACADEMY OF MEDICAL SCIENCES

Inventors

Shuyi Si, Yanni Xu, Xiao Wang, Jinque Luo, Yongzhen Li, Chao Liu, Xinhai Jiang, Yining Li, Xiaowan Han, Yan Li, Minghua Chen, Jing Zhang, Xin Zhen

Abstract

The disclosure relates to an indolo[2′,3′:3,4]pyrido[2,1-b]quinazoline compound represented by general formula (I) and use thereof in the manufacture of (1) a medicament for treating a cardiovascular and cerebrovascular disease, (2) a formulation for increasing expression of AMPK, ABCA1 and SR-BI, (3) a formulation for activating nuclear receptors (NRs), and inhibiting activity of NLRP3, IL-1β, NF-κB and MAPKs, (4) a formulation for promoting cellular cholesterol efflux; or (5) a medicament for anti-inflammation.